Fig. 5: Secondary AML according to the SLA.

Definition of secondary AML in 409 patients based on an association of clinical (history of MDS or MPN), molecular (mutations in any of the eight genes frequently altered in MDS [37]) and/or karyotypic abnormalities as defined by WHO.